Effects of the chemotherapeutic agents for non-hodgkin lymphoma, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), on the male rat reproductive system and progeny outcome

被引:34
|
作者
Vaisheva, Farida
Delbes, Geraldine
Hales, Barbara F.
Robaire, Bernard
机构
[1] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada
[2] McGill Univ, Dept Obstet & Gynecol, Montreal, PQ, Canada
来源
JOURNAL OF ANDROLOGY | 2007年 / 28卷 / 04期
关键词
anticancer drugs; spermatogenesis; male germ cell; apoptosis; adverse effects; developmental toxicity;
D O I
10.2164/jandrol.106.002428
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Chemotherapy of non-Hodgkin lymphoma (NHL) with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is associated with significant gonadal damage. Our goal was to determine the impact of CHOP chemotherapy on the male reproductive system, fertility, and progeny outcome in the rat model. Adult male Sprague-Dawley rats received saline or CHOP, 4 cycles of 3 weeks each, at doses analogous to 1/3 x, 2/3 x, or 1 x the human dose; males were mated to evaluate effects on progeny outcome. Reproductive organ weights were significantly decreased in the 1 x CHOP-exposed group. The spermatozoal contents of the testes and epididymides were decreased in 1 X CHOP-treated males; the 1/3 x and 2/3 x doses also affected testicular sperm contents. Seminiferous tubule diameters were decreased by 20% in 1 X CHOP-treated males. Damage ranged from the presence of small vacuoles in the epithelium to tubules deprived of spermato- cytes and spermatids and was accompanied by an increased incidence of germ cell apoptosis. The acridine orange assay revealed a significant increase in sperm with abnormal DNA integrity profiles in the 1 X CHOP group. Despite effects on germ cell number and quality, CHOP-exposed rats remained fertile. However, a 50% decrease in live fetuses was observed in litters sired by 1 x CHOP-treated males due to a significant increase in both pre-implantation and postimplantation losses; postimplantation loss was also elevated among litters sired by 2/3 X CHOP-treated males. Thus, CHOP treatment affected both the quantity and quality of male germ cells; conceptal loss is a sensitive measure of the integrity of the male genome.
引用
收藏
页码:578 / 587
页数:10
相关论文
共 50 条
  • [41] A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma.
    Tulpule, A
    Duran, CA
    Smith, DL
    Berman, NE
    Buchanan, L
    Gorospe, G
    Boswell, W
    Nathwani, B
    Levine, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 593S - 593S
  • [42] Liposomal doxorubicin (TLC-D99) in combination with cyclophosphamide (C), vincristine (V), and prednisone (P) is active in newly diagnosed aggressive non-Hodgkin's lymphoma (NHL).
    Tulpule, A
    Espina, BM
    Berman, N
    Buchanan, LH
    Boswell, WD
    Welles, L
    Levine, AM
    BLOOD, 2001, 98 (11) : 346A - 346A
  • [43] Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma
    Unterhalt, M
    Herrmann, R
    Tiemann, M
    Parwaresch, R
    Stein, H
    Trumper, L
    Nahler, M
    ReussBorst, M
    Tirier, C
    Neubauer, A
    Freund, M
    Kreuser, ED
    Dietzfelbinger, H
    Bodenstein, H
    Engert, A
    Stauder, R
    Eimermacher, H
    Landys, K
    Hiddemann, W
    LEUKEMIA, 1996, 10 (05) : 836 - 843
  • [44] Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)
    M. Herold
    A. Schulze
    D. Niederwieser
    A. Franke
    H. J. Fricke
    P. Richter
    M. Freund
    B. Ismer
    K. Dachselt
    C. Boewer
    V. Schirmer
    J. Weniger
    R. Pasold
    C. Winkelmann
    C. Klinkenstein
    M. Schulze
    H. Arzberger
    K. Bremer
    S. Hahnfeld
    A. Schwarzer
    C. Müller
    Chr. Müller
    Journal of Cancer Research and Clinical Oncology, 2006, 132 : 105 - 112
  • [45] Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study
    Dyer, Martin J. S.
    Grigg, Andrew P.
    Gonzalez Diaz, Marcos
    Dreyling, Martin
    Rule, Simon
    Lei, Guiyuan
    Wassner-Fritsch, Elisabeth
    Fingerle-Rowson, Geunter
    Marlton, Paula V.
    BLOOD, 2014, 124 (21)
  • [46] Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma:: results of a randomised phase III trial (OSHO# 19)
    Herold, M
    Schulze, A
    Niederwieser, D
    Franke, A
    Fricke, HJ
    Richter, P
    Freund, M
    Ismer, B
    Dachselt, K
    Boewer, C
    Schirmer, V
    Weniger, J
    Pasold, R
    Winkelmann, C
    Klinkenstein, C
    Schulze, M
    Arzberger, H
    Bremer, K
    Hahnfeld, S
    Schwarzer, A
    Müller, C
    Müller, C
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (02) : 105 - 112
  • [47] Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma
    Katsuya, Hiroo
    Suzumiya, Junji
    Sasaki, Hidenori
    Ishitsuka, Kenji
    Shibata, Takao
    Takamatsu, Yasushi
    Tamura, Kazuo
    LEUKEMIA & LYMPHOMA, 2009, 50 (11) : 1818 - 1823
  • [48] A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.
    Borchmann, P
    Schnell, R
    Morschhauser, F
    Hess, G
    Harousseau, JL
    Herbrecht, R
    Derigs, HG
    Dreyfus, F
    Schouten, HC
    Engert, A
    Camboni, G
    BLOOD, 2003, 102 (11) : 642A - 642A
  • [49] Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255
    Lichtman, SM
    Niedzwiecki, D
    Barcos, M
    Carlisle, TL
    Cooper, MR
    Johnson, JL
    Peterson, BA
    ANNALS OF ONCOLOGY, 2000, 11 (09) : 1141 - 1146
  • [50] Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin's lymphoma: A systematic review and meta-analysis
    Lu, Bin
    Shen, Longfei
    Ma, Ying
    Qi, Jia
    Li, Yulin
    Wang, Zhihao
    Han, Lu
    Zhong, Ming
    FRONTIERS IN PHARMACOLOGY, 2022, 13